Gefitinib has demonstrated potential therapeutic activity in HNSCC in vivo by blocking basal EGFR-mediated mitogenic signaling.260 Combination therapy with paclitaxel and EGFR inhibitors improved prognosis in a mouse model of oral cancer by promoting cell apoptosis. This evidence concerns the gene EGFR and lip and oral cavity carcinoma.